Adjuvant immunotherapy for cancer: From basic research to clinical bench

Inflammation and Immunity in Cancer

Volumn , Issue , 2015, Pages 229-241

  Matsumoto, Misako ^a   Azuma, Masahiro ^a   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cells; Immunotherapy; Innate immunity; Interferons; Macrophages; Pam2 lipopeptides; Pattern recognition; Polyi: c

Indexed keywords

EID: 84943409123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55327-4_18     Document Type: Chapter

References (56)

1. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, Takahashi T, Ikawa M, Okabe M, Inoue N, Okamoto-Tanaka M, Ishizaki H, Miyoshi J, Matsumoto M, Seya T (2007) Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 104(1):252–257
2. Azuma I, Ribi EE, Meyer TJ, Zbar B (1974) Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl CancerInst 52(1):95–101
3. Azuma M, Sawahata R, Akao Y, Ebihara T, Yamazaki S, Matsumoto M, Hashimoto M, Fukase K, Fujimoto Y, Seya T (2010) The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One 5(9):e12550
4. Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T (2012) Cross-priming for antitumor CTLinduced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells. Onco immunology 1(5):581–592
5. Azuma M, Takeda Y, Okada S, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, Matsumoto M, Seya T (2015) BATF3 in CD8a+DC sustains TLR3-derived IL-12 induction and CD11c+ antitumorT cell responses during antigen + poly(I:C) treatment. Cancer Res Immunol (submitted)
6. Bell JK, Askins J, Hall PR, Davies DR, Segal DM (2006) The dsRNA binding site of human Tolllike receptor 3. Proc Natl Acad Sci U S A 103(23):8792–8797
7. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, Breton G, Trumpfheller C, Pollak S, Shimeliovich I, Duque-Alarcon A, Pan L, Nelkenbaum A, Salazar AM, Schlesinger SJ, Steinman RM, Sékaly RP (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208(12):2357–2366
8. Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199–200
9. Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L (2010) Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 70(2):490–500
10. Desmet CJ, Ishii KJ (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12(7):479–491
11. Ebihara T, Azuma M, Oshiumi H, Kasamatsu J, Iwabuchi K, Matsumoto K, Saito H, Taniguchi T, Matsumoto M, Seya T (2010) Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 207(12):2675–2687
12. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G (2012) Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Onco immunology 1(5):699–716
13. Honda K, Takaoka A, Taniguchi T (2006) Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25(3):349–360
14. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, Kinoshita T, Akira S, Yoshikai Y, Yamasaki S (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206(13):2879–2888
15. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, Han SH, Lee H, Paik SG, Lee JO (2009) Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31:873–884
16. Kasamatsu J, Azuma M, Oshiumi H, Morioka Y, Okabe M, Ebihara T, Matsumoto M, Seya T (2014) INAM plays a critical role in IFN-g production by NK cells interacting with poly inosinic polycytidylic acid-stimulated accessory cells. J Immunol 193:5199–5207
17. Kasamatsu J, Takahashi S, Azuma M, Matsumoto M, Morii-Sakai A, Imamura M, Teshima T, Takahashi A, Hirohashi Y, Torigoe T, Sato N, Seya T (2015) PolyI: C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin inHLA-A*2402 transgenic mice. Immunobiology 220:74–82
18. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457(7225):102–106
19. Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, Akazawa T, Matsumoto M, Seya T, Wada M, Hayashi A, Toyoshima K (2009) Innate immune therapy with a BCG cell wall skeleton after radical surgery for non-small cell lung cancer: a case control study. Surg Today 39:194–200
20. Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279–289
21. Koyasu S, Moro K, Tanabe M, Takeuchi T (2010) Natural helper cells: a new player in the innate immune response against helminth infection. Adv Immunol 108:21–44
22. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325(17):1205–1209
23. Levine AS, Sivulich M, Wiernik PH, Levy HB (1979) Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxy methylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res 39(5):1645–1650
24. Levy HB, Law LW, Rabson AS (1969) Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A 62(2):357–361
25. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320:379–381
26. Maruyama C (1971) Treatment of malignant tumors by an extract from tubercle bacilli (tuberculosis vaccine) [in Japanese]. Nihon Ika Daigaku Zasshi 38(5):267–276
27. Maruyama A, Shime H, Takeda Y, Azuma M, Matsumoto M, Seya T. (2015) Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun 457(3):445–450
28. Matsumoto M, Seya T (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60:805–812
29. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T (2003) Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 171(6):3154–3162
30. Matsumoto M, Tatematsu M, Nishikawa F, Azuma M, Shime H, Seya T (2015) Defined TLR3- specific adjuvant that induces NK and cytotoxic T cell activation without significant cytokineproduction in vivo. Nat Commun 6:6280
31. Medzhitov R, Janeway CA Jr (1997) Innate immunity: the virtues of a nonclonal system of recognition. Cell 91(3):295–298
32. Murata M (2008) Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 99(7):1435–1440
33. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A (2008) Tolllike receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alphadependent mechanism. Carcinogenesis 29(7):1334–1342
34. Pardoll DM (2002) Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2(4):227–238
35. Ray A, Cot M, Puzo G, Gilleron M, Nigou J (2013) Bacterial cell wall macro amphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie 95(1):33–42
36. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915
37. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, Agger EM, Stenger S, Andersen P, Ruland J, Brown GD, Wells C, Lang R (2010) Cutting edge:Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 184(6):2756–2760
38. Seya T, Matsumoto M, Tsuji S, Begum NA, Azuma I, Toyoshima K (2002) Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect 4(9):955–961
39. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K (2003) Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23(6a):4369–4376
40. Seya T, Shime H, Takaki H, Azuma M, Oshiumi H, Matsumoto M (2012) TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis. Onco immunology 1(6):917–923
41. Seya T, Azuma M, Matsumoto M (2013) Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opin Ther Targets 17(5):533–544
42. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T (2012) Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A 109(6):2066–2071
43. Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T (2014) Myeloidderived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 6(3):293–305
44. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, Powrie F, Vivier E (2013) Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145–149
45. Takeda Y, Azuma M, Hatsugai R, Akazawa T, Ebihara T, Matsumoto M, Seya T (2015) Efficient MyD 88-dependent cross-priming and EG7 tumor regression induced by mycoplasma lipopeptideMALP-2s. (submitted)
46. Takemura R, Takaki H, Shime H, Oshiumi H, Matsumoto M, Tejima T, Seya T (2015) Necroptosis induced by the TICAM-1-RIP1/3 pathway in CT26 cells. Cancer Immunol Res (in press)
47. Taniguchi T, Mantei N, Schwarzstein M, Nagata S, Muramatsu M, Weissmann C (1980) Human leukocyte and fibroblast interferons are structurally related. Nature 285(5766):547–549
48. Tatematsu M, Nishikawa F, Seya T, Matsumoto M (2013) Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nat Commun 4:1833
49. Tokunaga T, Yamamoto T, Yamamoto S (1999) How BCG led to the discovery of immune stimulatory DNA. Jpn J Infect Dis 52(1):1–11
50. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillusCalmette-Guérin: involvement of toll-like receptors. Infect Immun 68(12):6883–6890
51. Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K, Shingai M, Matsumoto M, Azuma I, Toyoshima K, Kusumoto S, Seya T (2005) Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 174(11):7096–7103
52. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial Watch: Toll-like receptor agonists for cancer therapy. Onco Immunology 2(8):e25238
53. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643–1647
54. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T (2011) TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 6(4):e18833
55. Yamazaki S, Maruyama A, Okada K, Matsumoto M, Morita A, Seya T (2012) Dendritic cells from oral cavity induce Foxp3(+) regulatory T cells upon antigen stimulation. PLoS One 7:e51665
56. Yasumoto K, Manabe H, Yanagawa E, Nagano N, Ueda H, Hirota N, Ohta M, Nomoto K, Azuma I, Yamamura Y (1979) Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin. Cancer Res 39:3262–3267